Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission.

Sotty F, Damgaard T, Montezinho LP, Mørk A, Olsen CK, Bundgaard C, Husum H.

J Pharmacol Exp Ther. 2009 Mar;328(3):951-62. doi: 10.1124/jpet.108.146944. Epub 2008 Dec 19.

2.

The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.

Hansen HH, Ebbesen C, Mathiesen C, Weikop P, Rønn LC, Waroux O, Scuvée-Moreau J, Seutin V, Mikkelsen JD.

J Pharmacol Exp Ther. 2006 Sep;318(3):1006-19. Epub 2006 Jun 14.

3.

The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine.

Hansen HH, Andreasen JT, Weikop P, Mirza N, Scheel-Krüger J, Mikkelsen JD.

Eur J Pharmacol. 2007 Sep 10;570(1-3):77-88. Epub 2007 Jun 5.

PMID:
17628530
4.

The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices.

Jensen MM, Lange SC, Thomsen MS, Hansen HH, Mikkelsen JD.

Basic Clin Pharmacol Toxicol. 2011 Nov;109(5):339-42. doi: 10.1111/j.1742-7843.2011.00730.x. Epub 2011 Jun 25.

6.
7.

Retigabine, the specific KCNQ channel opener, blocks ectopic discharges in axotomized sensory fibres.

Roza C, Lopez-Garcia JA.

Pain. 2008 Sep 15;138(3):537-45. doi: 10.1016/j.pain.2008.01.031. Epub 2008 Mar 10.

PMID:
18331780
9.
10.

The pan-Kv7 (KCNQ) Channel Opener Retigabine Inhibits Striatal Excitability by Direct Action on Striatal Neurons In Vivo.

Hansen HH, Weikop P, Mikkelsen MD, Rode F, Mikkelsen JD.

Basic Clin Pharmacol Toxicol. 2017 Jan;120(1):46-51. doi: 10.1111/bcpt.12636. Epub 2016 Aug 23.

11.

The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain.

Blackburn-Munro G, Jensen BS.

Eur J Pharmacol. 2003 Jan 24;460(2-3):109-16.

PMID:
12559370
12.

Kv7 (KCNQ) channel openers induce hypothermia in the mouse.

Kristensen LV, Sandager-Nielsen K, Hansen HH.

Neurosci Lett. 2011 Jan 20;488(2):178-82. doi: 10.1016/j.neulet.2010.11.024. Epub 2010 Nov 16.

PMID:
21087654
13.

The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.

Dost R, Rostock A, Rundfeldt C.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Apr;369(4):382-90. Epub 2004 Mar 9.

PMID:
15007538
14.

Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352.

Dupuis DS, Schrøder RL, Jespersen T, Christensen JK, Christophersen P, Jensen BS, Olesen SP.

Eur J Pharmacol. 2002 Feb 22;437(3):129-37.

PMID:
11890900
15.

The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.

Gunthorpe MJ, Large CH, Sankar R.

Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5. Review.

16.

KCNQ/Kv7 channel regulation of hippocampal gamma-frequency firing in the absence of synaptic transmission.

Piccinin S, Randall AD, Brown JT.

J Neurophysiol. 2006 May;95(5):3105-12. Epub 2006 Feb 8.

PMID:
16467425
17.

Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission.

Piazza PV, Barrot M, Rougé-Pont F, Marinelli M, Maccari S, Abrous DN, Simon H, Le Moal M.

Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15445-50.

18.

Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder.

Rode F, Svalø J, Sheykhzade M, Rønn LC.

Eur J Pharmacol. 2010 Jul 25;638(1-3):121-7. doi: 10.1016/j.ejphar.2010.03.050. Epub 2010 Apr 10.

PMID:
20385123
19.

KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.

Zhang D, Thimmapaya R, Zhang XF, Anderson DJ, Baranowski JL, Scanio M, Perez-Medrano A, Peddi S, Wang Z, Patel JR, DeGoey DA, Gopalakrishnan M, Honore P, Yao BB, Surowy CS.

J Neurosci Methods. 2011 Aug 30;200(1):54-62. doi: 10.1016/j.jneumeth.2011.06.014. Epub 2011 Jun 23.

PMID:
21723881
20.

Retigabine: chemical synthesis to clinical application.

Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro RE.

CNS Drug Rev. 2005 Spring;11(1):1-20. Review.

Supplemental Content

Support Center